Power Metal Resources #POW – CEO Paul Johnson tells Proactive’s Andrew Scott why he’s committed for the long-term
Power Metal Resources PLC’s (LON:POW) Paul Johnson speaks to Proactive London’s Andrew Scott soon after buying 2mln shares in the explorer taking his stake to 4.9%. Johnson says he has a great deal of confidence in the company and its assets and in order to help realise the potential he feels they have he’s planning […]
Tiziana CEO Kunwar Shailubhai discusses the company’s anti il6 technology to deliver drugs to lungs with Andrew Scott at Proactive Investors
Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO and chief scientific officer Kunwar Shailubhai discusses the recent excitement around inhalation and the direct delivery of drugs to lungs. ”It makes a lot of sense”, he says. Shailubhai says he’s pleased he’s covered this approach in his recent patent and in fact was one of the first to do […]
Open Orphan #ORPH Exec Chairman Cathal Friel speaks to Proactive’s Andrew Scott about the new US biotech deal
Open Orphan PLC’s (LON:ORPH) Cathal Friel speaks to Proactive London’s Andrew Scott after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study.
Macarthur Minerals buoyed by share spike for major shareholder Cadence Minerals on iron ore deal – Proactive Investors
by John Miller. Macarthur is also encouraged by a robust iron ore market enhanced by low shipping rates and low oil prices. Macarthur Minerals Limited (ASX:MIO) (CVE:MMS) remains focused on bringing to production its Western Australia iron ore projects, with the price of the key commodity remaining robust and largely unaffected by the COVID-19 pandemic. […]
Open Orphan: Flu vaccine data showcased in peer reviewed article – Proactive Investors
by Ian Lyall. FLU-v has been developed by Imutex, 49%-owned by Open Orphan unit hVIVO The results of a successful phase IIb trial of a potential flu vaccine being developed by an Open Orphan PLC (LON:ORPH) joint-venture have been written up in a peer-reviewed article carried by a scientific journal. The data from FLU-v 004 […]
Cadence Minerals chief provides upbeat assessment of Brazil iron ore project as green light is given for stockpile exports – Proactive Investors
by Ian Lyall. Speaking to Proactive’s Andrew Scott earlier, Kiran Morzaria said the former Anglo American and Cliffs Natural Resources mine, which is in the north of the country, had been “substantially de-risked” Cadence Minerals PLC (LON:CNC) chief executive, Kiran Morzaria, provided an upbeat assessment of the potential of the Amapá iron ore project in […]
Cadence CEO Kiran Morzaria interview with Andrew Scott of ProActive Investors
Cadence CEO Kiran Morzaria & Andrew Scott of ProActive Investors discuss the recent Court Approval to ship iron ore stockpiles at its Amapá project in Brazil, marking a significant step forward for the company & asset
Proactive Investors – Open Orphan #ORPH catching global attention with ‘stunning’ FLU-v results & world-first coronavirus study
Open Orphan PLC‘s (LON:ORPH) Cathal Friel and its subsidiary hVIVO’s chief scientist Dr Andrew Catchpole sat down with Proactive London’s Andrew Scott. This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they’re jointly developing have been published in a peer-reviewed journal. The data from the FLU-v 003 […]
Proactive Investors interview with the Open Orphan #ORPH team on its future and ‘the lottery ticket’ sitting within hVIVO
Open Orphan PLC‘s (LON:ORPH) Cathal Friel speaks to Proactive London’s Andrew Scott following the completion last week of its £5.3mln fundraise. Also in studio is adviser to Open Orphan and founder of hVivo Professor John Oxford. Professor Oxford’s been a leader in the field of vaccine and anti-viral clinical trials for the last 20 years. […]
Cathal Friel, Open Orphan #ORPH CEO confirms to Proactive Investors that the hVIVO deal is done
Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. Cathal also provides some news on the Genomic Database and explains how he expects hVIVO to make a profit.